• Client Login
Ozmosi
  • Services
    • BEAM Clinical Trial Data
    • GCT Global Clinical Trials
    • PRYZM Pharma Product Database
    • PDUFA Calendar
    • KRYSTL Industry Scan Reporting
    • LENZ Company Pipeline Summary
    • Specialized Consulting
    • Approved Pharmaceutical Products in Use
  • About Us
  • Case Studies
  • Newsroom
  • Contact Us
Select Page
Novo Nordisk Diabetes Pipeline Analysis

Novo Nordisk Diabetes Pipeline Analysis

May 22, 2025 | Chronic Disease, Diabetes, Disease Area Trends

Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog®  and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...

Recent Posts

  • Market Overview: GLP-1 Agonists and the Obesity MarketJune 12, 2025
  • How Next-Generation Probability of Success Forecasting Can Improve Clinical Trial Accuracy by 44%June 12, 2025
  • Not Your Grandparents’ Probability of Success ForecastsJune 5, 2025
  • Clinical Trial Success Rates: What Makes Some Companies Stand Out?June 5, 2025
  • FDA Accelerated Approval, Breakthrough Therapy, and Fast Track Designations Supercharge Drug DevelopmentMay 26, 2025
  • Uncovering New Catalyst Events in the Pharmaceutical and Biotech MarketsMay 26, 2025
  • Home
  • About Us
  • Services
  • Case Studies
  • Newsroom
  • Contact Us
  • Facebook
  • X
OZMOSI© 2025 | All Rights Reserved | Site by Webtyde